Clinical research, reduced to its practical signal.
JAMA Editors' Summary is a fast, editorial briefing on newly published JAMA studies, research letters, viewpoints, and accompanying editorials. It suits listeners who want the population, outcome, result, and practice implication without extra conversation.
PRESS PLAY
JAMA Editors' Summary is a weekly evidence briefing with the cadence of a medical journal meeting. It is concise, formal, and built around what changed in the literature. The format usually begins with several clinical questions, then moves article by article through methods, findings, interpretation, and caution. It favors clarity over drama. Recent episodes cover dyslipidemia guidelines, ischemic stroke thrombectomy, safe sleep interventions, Alzheimer disease biomarkers, HPV self-collection, GLP-1 prescribing, lung transplant for select cancer patients, and AI tools in clinical work. The show is broad without feeling scattered, because each segment returns to the same practical question: what should clinicians take from this now? That discipline matters. A trial of thrombectomy in medium or distal artery stroke is not treated as a technology story, but as an outcomes story where safety concerns and functional recovery carry the weight. Alzheimer disease coverage shows the same restraint. Blood-based P-tau217 levels are presented as promising for prognosis and prevention trial design, while the episode keeps individual clinical prediction outside the current evidence. The program also gives space to health systems and policy. Episodes discuss online GLP-1 prescribing, insurance denials, AI mental health harms, law enforcement deaths, mifepristone pharmacy access, and deaths in ICE detention. These segments keep the medical frame intact while acknowledging that care is shaped by regulation, surveillance, access, and institutional practice. The voice is polished and report-like. It rarely lingers for personality, and that is part of its utility. Named editors such as Dr. Preeti Malani, Dr. Linda Brubaker, and Dr. Kirsten Bibbins-Domingo bring continuity, with occasional guest participation when a major study warrants added perspective. The best fit is a listener who already knows the language of medicine but wants help triaging a dense publication week. It is not a bedside explainer for beginners. It is a compact editorial map for people who need to keep current and know where uncertainty remains.
Made for: Best for clinicians, medical researchers, trainees, health policy readers, and medically fluent listeners who want a disciplined scan of new JAMA evidence. It assumes comfort with clinical terminology and study design.
What sets it apart: The show compresses journal content into a tightly edited sequence of study question, population, outcome, limitation, and practice meaning. Its edge is not personality; it is editorial control and restraint.
Weekly Editors' Audio Summary for JAMA, the Journal of the American Medical Association
Short reviews from the PlayNext desk, based on the episodes we processed.
A brisk ESC roundup that ties trial design to clinical practice.
JAMA's ESC special pulls together a busy cardiology lineup, moving from remote ECG patch screening for asymptomatic atrial fibrillation to heart failure treatments, vaccination's cardiovascular effects, and a close comparison of TAVR and SAVR in aortic stenosis.
Oncology evidence translated into clinical decisions.
Critical care evidence, carefully talked through.
Evidence translated into clinical next steps.
This special JAMA Editors' Summary covers key cardiology research presented at the European Society of Cardiology Congress.
Dr.
This JAMA Editor Summary episode discusses recent medical research including a clinical trial on coffee consumption after cardioversion for atrial fibrillation, along with updates on metabolic dysfunction-associated steatototic liver disease and primary biliary cholangitis.
This JAMA Editor's Summary episode reviews nine research papers presented at the American Heart Association Scientific Sessions, focusing on studies about coffee consumption and atrial fibrillation, DASH-patterned groceries' effects on blood pressure, and an oral PCSK9 inhibitor for heterozygous familial hypercholesterolemia.
This JAMA Editor's Summary episode discusses recent medical research findings on transcatheter tricuspid valve replacement outcomes, antibiotic use for surgical site infections in tibial fractures, and the ethical implications of AI prescribing medications.
This JAMA Editor's Summary discusses research on discontinuing levothyroxine in older adults, cost-effective lipid-lowering goals, and colorectal cancer screening risks for seniors.
This JAMA Editor's Summary episode discusses the Vesalius CV trial on Evolocumab for reducing cardiovascular events in diabetic patients without significant atherosclerosis, along with topics like lead exposure and AI scribes in healthcare.
This JAMA Editor's Summary episode discusses a study on improving pediatric sepsis surveillance using a new EHR-based definition to better estimate incidence and mortality in U.S.
This JAMA Editor Summary episode discusses recent medical research findings including the ORCHESTRA trial on tumor debulking for metastatic colorectal cancer, physical restraints in ICU patients, and insulin costs for Medicare beneficiaries.
This JAMA Editor's Summary episode discusses recent research presented at the American Heart Association Scientific Sessions, focusing on a clinical trial investigating the effects of caffeinated coffee consumption on atrial fibrillation recurrence.
This special JAMA Editor's Summary podcast covers key cardiology research from the European Society of Cardiology Congress, including trials on remote monitoring for atrial fibrillation, semaglutide and tirzepatide for heart failure, and RSV vaccine effectiveness in older adults.
This JAMA Editor's Summary discusses clinical trial results for stapokibart in treating severe chronic rhinosinusitis with nasal polyps, along with other medical topics including toripalimab for nasopharyngeal carcinoma and climate impacts on drug manufacturing.